Cargando…

Revisiting CD28 Superagonist TGN1412 as Potential Therapeutic for Pediatric B Cell Leukemia: A Review

Pediatric acute lymphoblastic leukemia (ALL) represents the most common pediatric cancer diagnosis, with numbers rising gradually every year. This paper proposes a novel therapeutic agent for pediatric ALL on the basis of a failed clinical drug trial in 2006. TGN1412 was a promising therapeutic agen...

Descripción completa

Detalles Bibliográficos
Autor principal:	Brown, Katelyn E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023298/ https://www.ncbi.nlm.nih.gov/pubmed/29783736 http://dx.doi.org/10.3390/diseases6020041

Ejemplares similares

Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist
por: Thaventhiran, Thilipan, et al.
Publicado: (2014)

TGN1412: From Discovery to Disaster
por: Attarwala, H
Publicado: (2010)

Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm
por: Panoskaltsis, Nicki, et al.
Publicado: (2020)

After TGN1412: Recent developments in cytokine release assays
por: Stebbings, R., et al.
Publicado: (2013)

Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release
por: Eastwood, David, et al.
Publicado: (2013)

TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model
por: Weißmüller, Sabrina, et al.
Publicado: (2016)

CD28 Superagonist Shock and Blockage of Motogenic T Cell Cascade
por: Sundqvist, Karl-Gösta
Publicado: (2021)

Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies
por: Waibler, Zoe, et al.
Publicado: (2008)

Patients with gastrointestinal irritability after TGN1412-induced cytokine storm displayed selective expansion of gut-homing αβ and γδT cells
por: McCarthy, Neil E., et al.
Publicado: (2020)

Topological Requirements and Signaling Properties of T Cell–activating, Anti-CD28 Antibody Superagonists
por: Lühder, Fred, et al.
Publicado: (2003)

Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials — Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm
por: Vessillier, S., et al.
Publicado: (2015)

Rapid Regulatory T-Cell Response Prevents Cytokine Storm in CD28 Superagonist Treated Mice
por: Gogishvili, Tea, et al.
Publicado: (2009)

CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program
por: Thaventhiran, Thilipan, et al.
Publicado: (2019)

Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis
por: Beyersdorf, Niklas, et al.
Publicado: (2005)

Self-Recognition Sensitizes Mouse and Human Regulatory T Cells to Low-Dose CD28 Superagonist Stimulation
por: Langenhorst, Daniela, et al.
Publicado: (2018)

Are there superagonists for calcium-activated potassium channels?
por: Brown, Brandon M., et al.
Publicado: (2017)

Inhibition of ZAP-70 Kinase Activity via an Analog-sensitive Allele Blocks T Cell Receptor and CD28 Superagonist Signaling
por: Levin, Susan E., et al.
Publicado: (2008)

Combinations of anti-GITR antibody and CD28 superagonist induce permanent allograft acceptance by generating type 1 regulatory T cells
por: Que, Weitao, et al.
Publicado: (2022)

Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson’s disease mice
por: Badr, Mohammad, et al.
Publicado: (2022)

CD28 superagonist-mediated boost of regulatory T cells increases thrombo-inflammation and ischemic neurodegeneration during the acute phase of experimental stroke
por: Schuhmann, Michael K, et al.
Publicado: (2015)

Superagonistic CD28 protects against renal ischemia injury induced fibrosis through a regulatory T-cell expansion dependent mechanism
por: Liang, Yiran, et al.
Publicado: (2019)

Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties
por: Elsayed, Abdullah, et al.
Publicado: (2023)

Actin gets Hip at the TGN
por: Sreenivasan, Aparna
Publicado: (2004)

Protein sorting from endosomes to the TGN
por: Buser, Dominik P., et al.
Publicado: (2023)

Transferrin receptor containing the SDYQRL motif of TGN38 causes a reorganization of the recycling compartment but is not targeted to the TGN
Publicado: (1996)

An Endocytosed TGN38 Chimeric Protein Is Delivered to the TGN after Trafficking through the Endocytic Recycling Compartment in CHO Cells
por: Ghosh, Richik N., et al.
Publicado: (1998)

Secretory proteins hail a cab at the TGN
por: Short, Ben
Publicado: (2012)

The Vps13p–Cdc31p complex is directly required for TGN late endosome transport and TGN homotypic fusion
por: De, Mithu, et al.
Publicado: (2017)

The Story of CD4(+)CD28(−) T Cells Revisited: Solved or Still Ongoing?
por: Maly, Kathrin, et al.
Publicado: (2015)

Safety and Effectiveness of Blind Percutaneous Liver Biopsy: Analysis of 1412 Procedures
por: Szymczak, Aleksandra, et al.
Publicado: (2012)

1412. Caspofungin and Anidulafungin Behave as Fungistatic Agents Against Candida auris
por: Dudiuk, Catiana, et al.
Publicado: (2018)

1412. Bioburden Reduction: Introduction of a novel skin antiseptic solution
por: Fernández-Rodríguez, Diana, et al.
Publicado: (2023)

The Tlg SNARE complex is required for TGN homotypic fusion
por: Brickner, Jason H., et al.
Publicado: (2001)

Perturbation of the morphology of the trans-Golgi network following Brefeldin A treatment: redistribution of a TGN-specific integral membrane protein, TGN38
Publicado: (1992)

Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines
por: Ceglia, Valentina, et al.
Publicado: (2022)

Taltirelin is a superagonist at the human thyrotropin-releasing hormone receptor
por: Thirunarayanan, Nanthakumar, et al.
Publicado: (2012)

New Roles for Vitamin D Superagonists: From COVID to Cancer
por: Easty, David J., et al.
Publicado: (2021)

IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34(+) progenitor-derived NK cells
por: Van der Meer, J. M. R., et al.
Publicado: (2020)

Corrigendum to “The Story of CD4(+)CD28(−) T Cells Revisited: Solved or Still Ongoing?”
por: Maly, Kathrin, et al.
Publicado: (2015)

Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer
por: Wei, Pengcheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2hh9s5eaomir4dao4bggr1iavg